Table 3. Effect of afatinib, erlotinib and gemcitabine on the cell-cycle distribution of pancreatic cancer cell lines.
| Cell line/treatment | Sub-G1 | G0/G1 | S | G2/M |
|---|---|---|---|---|
| BxPc-3 | ||||
| Control | 8.7 | 57.3 | 21.9 | 12.2 |
| Afatinib | 21.8 | 50.1 | 16.5 | 9.9 |
| Gemcitabine | 35.5 | 11 | 46.3 | 5.6 |
| Erlotinib | 13.3 | 51.6 | 20.7 | 13.5 |
| AsPC-1 | ||||
| Control | 1 | 45.9 | 32 | 19.6 |
| Afatinib | 13.3 | 43.5 | 30.9 | 13.6 |
| Gemcitabine | 3.3 | 15.7 | 54.5 | 24.9 |
| Erlotinib | 8 | 44.8 | 31.7 | 14.5 |
| Capan-1 | ||||
| Control | 3.6 | 49.2 | 27.7 | 19.4 |
| Afatinib | 9.5 | 49.3 | 28.9 | 10.8 |
| Gemcitabine | 23 | 26.3 | 31.9 | 18.1 |
| PT-45 | ||||
| Control | 2.8 | 71.4 | 14.3 | 10.8 |
| Afatinib | 9 | 67.9 | 15.4 | 6.8 |
| Gemcitabine | 23.7 | 33.6 | 36.9 | 5.4 |
| MiaPaCa-2 | ||||
| Control | 6.5 | 74.6 | 9.1 | 8.7 |
| Afatinib | 15.1 | 45.9 | 19.6 | 17.6 |
| Gemcitabine | 9.1 | 34 | 33.4 | 20 |
| PANC-1 | ||||
| Control | 6.7 | 51.6 | 11.7 | 29.4 |
| Afatinib | 42.9 | 28 | 10.5 | 17.9 |
| Gemcitabine | 20.1 | 38.8 | 30.1 | 9.4 |
| FA6 | ||||
| Control | 15.2 | 50.5 | 22 | 11.5 |
| Afatinib | 27.1 | 37.9 | 23.7 | 8.2 |
| Gemcitabine | 26.1 | 40.4 | 25.2 | 9 |
Each population is expressed as a percentage of gated cells.